Key Metrics of Gilead Sciences
Revenue$27.1B▼ 0.6% YoYFY 2023
Operating income$7.6B▲ 3.8% YoY
Net profit$5.7B▲ 23.4% YoY
Shareholders' equity$22.8B
Market cap$195BGILD · $157.19
Competitors10identified
About Gilead Sciences
Part of Gilead Sciences.
Sectors
Company details
- Website
- gilead.com
- Founded
- 1992
- Registered office
- 1208-1209, 12th Floor, Vikrant Tower, Rajendra Place, Patel Nagar West, Central Delhi, New Delhi, In-dl, 110008
- Listed
- Nasdaq: GILD (since 1992)
Operational Areas of Gilead Sciences
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Entity details
CINU74120DL2014FTC308398
LEI code335800RFMJ46JSCCZW57
State codeDL
PIN code110008
Current legal nameGILEAD SCIENCES
Classification—
Listing statusUnlisted
Registration no.308398
Company age—
PAN—
CountryUnited States
CityNew Delhi
StateDelhi
Current statusActive
Date of incorporation—
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—
Compliance
Last AGM date—
Last balance sheet—
Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026
Industry classification
NIC code74120
Description of main activityOther business activities (consultancy, engineering, advertising, staffing)
Description of business activityOther business activities (consultancy, engineering, advertising, staffing)
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
US market & SEC filings
GILD · Nasdaq · SEC CIK 0000882095
Last price · 23 Oct 2026
$157.19
+2.36%
Market cap$195B
P/E34.9On FY 2023 diluted EPS
Volume6,210,523
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 1992
GILD share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
AGM for FY 2025-2630 Sep 2026
Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026
Statutory due date · 6 days left
MGT-7 for FY 2025-2629 Nov 2026
Statutory due date · 36 days left
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office1208-1209, 12TH FLOOR, VIKRANT TOWER, RAJENDRA PLACE, PATEL NAGAR WEST, CENTRAL DELHI, NEW DELHI, IN-DL, 110008
GSTIN—
Email—
Websitehttps://www.gilead.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Gilead Sciences
Competitors10identified
Locations1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | hcahealthcare.com | 2011 | United States |
Similar companies
B
Brooks Laboratories LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
M
Morepen Laboratories LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
N
Nectar Lifesciences LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
T
Themis Medicare LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Sakar Healthcare LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
I
IOL Chemicals and Pharmaceuticals Ltd. (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
P
Poly Medicure (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Suven Life Sciences (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Group companies
Part of Gilead Sciences
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.